Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial. - Heerspink, Hiddo J L; Jardine, Meg J; Kohan, Donald E; Lafayette, Richard; Levin, Adeera; Liew, Adrian; Zhang, Hong; Noronha, Irene L; Mastroianni-Kirsztajn, Gianna; Chow, Stephen; Choi, Dae Eun; Lv, Jicheng; et al. (Lancet, 2026)